Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

AIMS/HYPOTHESIS: In rodent models of diabetes, treatment with sodium glucose co-transporter 2 (SGLT2) inhibitors improves beta cell function. This analysis assessed the effects of the SGLT2 inhibitor, canagliflozin, on model-based measures of beta cell function in patients with type 2 diabetes. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Polidori, David, Mari, Andrea, Ferrannini, Ele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980039/
https://www.ncbi.nlm.nih.gov/pubmed/24585202
http://dx.doi.org/10.1007/s00125-014-3196-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980039/
https://www.ncbi.nlm.nih.gov/pubmed/24585202
http://dx.doi.org/10.1007/s00125-014-3196-x

Ejemplares similares